Immunotherapy strategies hold considerable promise as a prospective avenue for managing hypertensive end-organ damage driven by autoimmune responses and immune cell infiltration.
Do immunotherapy strategies improve outcomes in patients with hypertensive end-organ damage?
Immunotherapy represents a promising future therapeutic strategy for managing hypertensive end-organ damage driven by autoimmune responses.
Hypertension represents a highly prevalent chronic condition and stands among the foremost contributors to premature mortality on a global scale. Its etiopathogenesis is intricate and multifaceted, being shaped by a diverse array of elements such as age, genetic predisposition, and activation of the neuroendocrine apparatus. Mounting evidence has shed light on the significant part that autoimmune responses play in hypertension and the ensuing damage to end organs. Virtually all varieties of immune cells, spanning both innate and adaptive immune compartments, exhibit a close correlation with the progression of hypertension. These immune cells infiltrate the kidney and vascular mesenchyme, subsequently discharging potent cytokines, reactive oxygen species, and metalloproteinases. This cascade of events can affect the functionality of local blood vessels and potentially precipitate adverse structural and functional alterations in crucial organs like the heart and kidney. In recent times, the management of end-organ damage in hypertension has emerged as a pivotal scientific focus. A multitude of researchers are actively engaged in probing efficacious intervention regimens, among which immunotherapy strategies hold considerable promise and anticipation as a prospective avenue.
Xu et al. (Tue,) conducted a review in Hypertensive end-organ damage. Immunotherapy was evaluated. Immunotherapy strategies hold considerable promise as a prospective avenue for managing hypertensive end-organ damage driven by autoimmune responses and immune cell infiltration.